Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Ventilator Associated Pneumonia (VAP) Therapeutics Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Prevention
      • 1.3.3 Physiotherapy
      • 1.3.4 Immunity Therapy
    • 1.4 Market Segment by Application
      • 1.4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2019-2025)
      • 1.4.2 Hospitals
      • 1.4.3 Ambulatory Surgical Center
      • 1.4.4 Diagnostic Centers
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size
      • 2.1.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue 2014-2025
      • 2.1.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Sales 2014-2025
    • 2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Growth Rate by Regions
      • 2.2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Sales by Regions 2014-2019
      • 2.2.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Ventilator Associated Pneumonia (VAP) Therapeutics Sales by Manufacturers
      • 3.1.1 Ventilator Associated Pneumonia (VAP) Therapeutics Sales by Manufacturers 2014-2019
      • 3.1.2 Ventilator Associated Pneumonia (VAP) Therapeutics Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Ventilator Associated Pneumonia (VAP) Therapeutics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.3 Ventilator Associated Pneumonia (VAP) Therapeutics Price by Manufacturers
    • 3.4 Key Manufacturers Ventilator Associated Pneumonia (VAP) Therapeutics Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
    • 3.6 Key Manufacturers Ventilator Associated Pneumonia (VAP) Therapeutics Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Prevention Sales and Revenue (2014-2019)
      • 4.1.2 Physiotherapy Sales and Revenue (2014-2019)
      • 4.1.3 Immunity Therapy Sales and Revenue (2014-2019)
    • 4.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Sales Market Share by Type
    • 4.3 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type
    • 4.4 Ventilator Associated Pneumonia (VAP) Therapeutics Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Sales by Application

    6 United States

    • 6.1 United States Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Company
    • 6.2 United States Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Type
    • 6.3 United States Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Application

    7 European Union

    • 7.1 European Union Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Company
    • 7.2 European Union Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Type
    • 7.3 European Union Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Application

    8 China

    • 8.1 China Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Company
    • 8.2 China Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Type
    • 8.3 China Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Company
    • 9.2 Rest of World Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Type
    • 9.3 Rest of World Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Application
    • 9.4 Rest of World Ventilator Associated Pneumonia (VAP) Therapeutics Breakdown Data by Countries
      • 9.4.1 Rest of World Ventilator Associated Pneumonia (VAP) Therapeutics Sales by Countries
      • 9.4.2 Rest of World Ventilator Associated Pneumonia (VAP) Therapeutics Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Achaogen Inc
      • 10.1.1 Achaogen Inc Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Ventilator Associated Pneumonia (VAP) Therapeutics
      • 10.1.4 Ventilator Associated Pneumonia (VAP) Therapeutics Product Introduction
      • 10.1.5 Achaogen Inc Recent Development
    • 10.2 Adenium Biotech ApS
      • 10.2.1 Adenium Biotech ApS Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Ventilator Associated Pneumonia (VAP) Therapeutics
      • 10.2.4 Ventilator Associated Pneumonia (VAP) Therapeutics Product Introduction
      • 10.2.5 Adenium Biotech ApS Recent Development
    • 10.3 Aridis Pharmaceuticals LLC
      • 10.3.1 Aridis Pharmaceuticals LLC Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Ventilator Associated Pneumonia (VAP) Therapeutics
      • 10.3.4 Ventilator Associated Pneumonia (VAP) Therapeutics Product Introduction
      • 10.3.5 Aridis Pharmaceuticals LLC Recent Development
    • 10.4 AstraZeneca Plc
      • 10.4.1 AstraZeneca Plc Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Ventilator Associated Pneumonia (VAP) Therapeutics
      • 10.4.4 Ventilator Associated Pneumonia (VAP) Therapeutics Product Introduction
      • 10.4.5 AstraZeneca Plc Recent Development
    • 10.5 Bayer AG
      • 10.5.1 Bayer AG Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Ventilator Associated Pneumonia (VAP) Therapeutics
      • 10.5.4 Ventilator Associated Pneumonia (VAP) Therapeutics Product Introduction
      • 10.5.5 Bayer AG Recent Development
    • 10.6 Cardeas Pharma Corp
      • 10.6.1 Cardeas Pharma Corp Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Ventilator Associated Pneumonia (VAP) Therapeutics
      • 10.6.4 Ventilator Associated Pneumonia (VAP) Therapeutics Product Introduction
      • 10.6.5 Cardeas Pharma Corp Recent Development
    • 10.7 Destiny Pharma Ltd
      • 10.7.1 Destiny Pharma Ltd Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Ventilator Associated Pneumonia (VAP) Therapeutics
      • 10.7.4 Ventilator Associated Pneumonia (VAP) Therapeutics Product Introduction
      • 10.7.5 Destiny Pharma Ltd Recent Development
    • 10.8 Dong-A Socio Holdings Co Ltd
      • 10.8.1 Dong-A Socio Holdings Co Ltd Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Ventilator Associated Pneumonia (VAP) Therapeutics
      • 10.8.4 Ventilator Associated Pneumonia (VAP) Therapeutics Product Introduction
      • 10.8.5 Dong-A Socio Holdings Co Ltd Recent Development
    • 10.9 Lakewood-Amedex Inc
      • 10.9.1 Lakewood-Amedex Inc Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Ventilator Associated Pneumonia (VAP) Therapeutics
      • 10.9.4 Ventilator Associated Pneumonia (VAP) Therapeutics Product Introduction
      • 10.9.5 Lakewood-Amedex Inc Recent Development
    • 10.10 MedImmune LLC
      • 10.10.1 MedImmune LLC Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Ventilator Associated Pneumonia (VAP) Therapeutics
      • 10.10.4 Ventilator Associated Pneumonia (VAP) Therapeutics Product Introduction
      • 10.10.5 MedImmune LLC Recent Development
    • 10.11 Meiji Seika Pharma Co Ltd
    • 10.12 Merck & Co Inc
    • 10.13 Motif Bio Plc
    • 10.14 Nabriva Therapeutics AG
    • 10.15 Polyphor Ltd
    • 10.16 Shionogi & Co Ltd
    • 10.17 Tetraphase Pharmaceuticals Inc
    • 10.18 The Medicines Company
    • 10.19 Theravance Biopharma Inc
    • 10.20 Wockhardt Ltd
    • 10.21 Zavante Therapeutics Inc

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Ventilator Associated Pneumonia (VAP) Therapeutics Sales Channels
      • 11.2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Distributors
    • 11.3 Ventilator Associated Pneumonia (VAP) Therapeutics Customers

    12 Market Forecast

    • 12.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Sales and Revenue Forecast 2019-2025
    • 12.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Sales Forecast by Type
    • 12.3 Global Ventilator Associated Pneumonia (VAP) Therapeutics Sales Forecast by Application
    • 12.4 Ventilator Associated Pneumonia (VAP) Therapeutics Forecast by Regions
      • 12.4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Ventilator Associated Pneumonia (VAP) Therapeutics is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Ventilator Associated Pneumonia (VAP) Therapeutics.

      This report studies the global market size of Ventilator Associated Pneumonia (VAP) Therapeutics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Ventilator Associated Pneumonia (VAP) Therapeutics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Achaogen Inc
      Adenium Biotech ApS
      Aridis Pharmaceuticals LLC
      AstraZeneca Plc
      Bayer AG
      Cardeas Pharma Corp
      Destiny Pharma Ltd
      Dong-A Socio Holdings Co Ltd
      Lakewood-Amedex Inc
      MedImmune LLC
      Meiji Seika Pharma Co Ltd
      Merck & Co Inc
      Motif Bio Plc
      Nabriva Therapeutics AG
      Polyphor Ltd
      Shionogi & Co Ltd
      Tetraphase Pharmaceuticals Inc
      The Medicines Company
      Theravance Biopharma Inc
      Wockhardt Ltd
      Zavante Therapeutics Inc

      Market Segment by Product Type
      Prevention
      Physiotherapy
      Immunity Therapy

      Market Segment by Application
      Hospitals
      Ambulatory Surgical Center
      Diagnostic Centers

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Ventilator Associated Pneumonia (VAP) Therapeutics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Ventilator Associated Pneumonia (VAP) Therapeutics manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Ventilator Associated Pneumonia (VAP) Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now